DiaSorin offers a complete Infectious Disease line, in ELISA format and on the LIAISON® systems.
The LIAISON® Measles IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to measles virus in human serum or plasma samples. It is intended to be used as an aid in the determination of serological status to measles virus. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Measles IgG assay uses chemiluminescence immunoassay (CLIA) technology for the semi-quantitative determination of specific IgG antibodies to measles virus in human serum or plasma samples. It is intended to be used as an aid in the determination of serological status to measles virus. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Mumps IgG assay uses chemiluminescence immunoassay (CLIA) technology for the semi-quantitative determination of specific IgG antibodies to mumps virus in human serum or plasma samples. It is intended to be used as an aid in the determination of serological status to mumps virus. The test has to be performed on the LIAISON® analyzer family.
Â
The LIAISON® Mumps IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to mumps virus in human serum or plasma samples. It is intended to be used as an aid in the determination of serological status to mumps virus. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® VZV IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to varicella-zoster virus (VZV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® VZV IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to varicella-zoster virus (VZV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Treponema Screen assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of specific total antibodies to Treponema pallidum in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Chalmydia trachomatis IgG assay uses chemiluminescence immunoassay (CLIA) technology for the semi-quantitative determination of specific IgG antibodies to Chlamydia trachomatis in human serum or plasma samples.
The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Chalmydia trachomatis IgA assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to Chlamydia trachomatis in human serum or plasma samples.
The test has to be performed on the LIAISON® analyzer family.
The LIAISON® XL MUREX Chagas is a chemiluminescence immunoassay (CLIA) for the qualitative detection of antibodies to Trypanosoma cruzi (T. cruzi) in human serum and plasma. The assay is intended to screen individual human donors for the presence of antibodies to T. cruzi or as an aid for the diagnosis of Chagas disease. The test has to be performed on the LIAISON® XL Analyzers only.
The LIAISON® H. pylori IgG kit uses chemilumineshent immunoassay (CLIA) technology for the qualitative determination of IgG antibodies to Helicobacter pylori in human serum samples.
The test has to be performed on the LIAISON® Analyzer family.
Â
Other important diagnostic uses of infectious serology is in immunosuppressed patients and transplant donors/recipients, where the assessment of immune status may be fundamental. Infectious serology can also be of help in these patients in monitoring the course of disease during immunosuppressive therapy. Other serological markers (antibodies to VZV, Treponema pallidum, Measleas and Mumps and many others) are of paramount importance to establish accurate diagnosis.
For many years DiaSorin has maintained an extensive Menu of Serology assays in ELISA (microplate) format. Many of these assays have been adapted for use on the fully automated assay platform.